Format

Send to

Choose Destination
Eur Urol. 2012 May;61(5):908-13. doi: 10.1016/j.eururo.2012.01.018. Epub 2012 Jan 20.

A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence.

Author information

1
Department of Urology, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy. angelo.naselli@libero.it

Abstract

BACKGROUND:

Narrow band imaging (NBI) is an optical enhancement technology that filters white light into two bandwidths of illumination centered on 415nm (blue) and 540nm (green). NBI cystoscopy can increase bladder cancer (BCa) visualization and detection at the time of transurethral resection (TUR). NBI may therefore reduce subsequent relapse following TUR.

OBJECTIVE:

Assess the impact of NBI modality on 1-yr non-muscle-invasive BCa (NMIBC) recurrence risk.

DESIGN, SETTING, AND PARTICIPANTS:

Consecutive patients with overt or suspected BCa were included in a prospective study powered to test a 10% difference in 1-yr recurrence risk in favor of cases submitted to NBI TUR. Excluding patients with muscle-invasive BCa, negative pathologic examination, or without follow-up, the study population was composed of 148 subjects randomized from August 2009 to September 2010 to NBI TUR (76 cases) or white light (WL) TUR (72 cases).

INTERVENTION:

TUR was performed in NBI or standard WL modality.

MEASUREMENTS:

The 1-yr recurrence risks in NBI or WL TUR groups were compared using odds ratio (OR) point and interval estimates derived from logistic regression modeling.

RESULTS AND LIMITATIONS:

The 1-yr recurrence-risk was 25 of 76 patients (32.9%) in the NBI and 37 of 72 patients (51.4%) in the WL group (OR=0.62; p=0.0141). Simple and multiple logistic regression analyses provided similar OR points and interval estimates.

CONCLUSIONS:

TUR performed in the NBI modality reduces the recurrence risk of NMIBC by at least 10% at 1 yr.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01004211.

PMID:
22280855
DOI:
10.1016/j.eururo.2012.01.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center